1) Adverse event reporting and monitoring,
2) a lack of understanding who would be operationally responsible for the activity, and
3) the company’s inability to respond in a timely fashion compared with the expectations of those who interact in a social media circles, are all barriers that suggest to us adoption will be slow and deliberate.
I also believe that the industry has had its wings clipped in its ability to generate relevant medical content – and people in social media crave this information.
Interview with BioPharma Advisors’ Robert Naumann